Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women's Healthcare InitiativesGlobeNewsWire • 04/18/24
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate UpdateGlobeNewsWire • 03/28/24
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment LandscapeGlobeNewsWire • 03/21/24
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of InfertilityGlobeNewsWire • 03/20/24
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility SolutionGlobeNewsWire • 03/06/24
Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVFGlobeNewsWire • 02/28/24
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial OfficerGlobeNewsWire • 02/06/24
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for WomenGlobeNewsWire • 01/26/24
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and GynecologyGlobeNewsWire • 01/23/24
Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical OfficerGlobeNewsWire • 11/30/23
Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial LaunchGlobeNewsWire • 11/28/23
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.Business Wire • 11/15/23
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte BiotechGlobeNewsWire • 11/15/23
Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate UpdateGlobeNewsWire • 11/14/23
Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive MedicineGlobeNewsWire • 10/04/23
Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to ParticipateGlobeNewsWire • 09/27/23